Trial · NCT03905694
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Lumasiran | Lumasiran | Month 24 | 3.73 | Full Range 1.67 to 10.3 | hours (h) |
| Elimination Half-life (t1/2beta) of Lumasiran | Lumasiran | Day 1 | 5.46 | Full Range 1.42 to 10.3 | hours (h) |
| Elimination Half-life (t1/2beta) of Lumasiran | Lumasiran | Month 6 | 5.96 | Full Range 3.04 to 9 | hours (h) |
| Elimination Half-life (t1/2beta) of Lumasiran | Lumasiran | Month 12 | 3.52 | Full Range 1.56 to 6.64 | hours (h) |
| Elimination Half-life (t1/2beta) of Lumasiran | Lumasiran | Month 18 | 3.74 | Full Range 1.62 to 13.9 | hours (h) |
| Elimination Half-life (t1/2beta) of Lumasiran | Lumasiran | Month 24 | 4.99 | Full Range 2.69 to 10.8 | hours (h) |
| Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Lumasiran | Lumasiran | Day 1 | 8050 | Geometric Coefficient of Variation 37.7 | hours*nanograms per milliliter (h*ng/mL) |
| Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Lumasiran | Lumasiran | Month 6 | 8450 | Geometric Coefficient of Variation 41.1 | hours*nanograms per milliliter (h*ng/mL) |
| Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Lumasiran | Lumasiran | Month 12 | 10800 | Geometric Coefficient of Variation 39.3 | hours*nanograms per milliliter (h*ng/mL) |
| Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Lumasiran | Lumasiran | Month 18 | 8420 | Geometric Coefficient of Variation 57.2 | hours*nanograms per milliliter (h*ng/mL) |
| Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Lumasiran | Lumasiran | Month 24 | 7420 | Geometric Coefficient of Variation 61.6 | hours*nanograms per milliliter (h*ng/mL) |
| Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-last) of Lumasiran | Lumasiran | Day 1 | 7870 | Geometric Coefficient of Variation 33.4 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-last) of Lumasiran | Lumasiran | Month 6 | 6620 | Geometric Coefficient of Variation 95.5 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-last) of Lumasiran | Lumasiran | Month 12 | 8480 | Geometric Coefficient of Variation 76.1 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-last) of Lumasiran | Lumasiran | Month 18 | 5770 | Geometric Coefficient of Variation 155.0 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-last) of Lumasiran | Lumasiran | Month 24 | 7100 | Geometric Coefficient of Variation 80.0 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Infinity (AUC0-infinity) of Lumasiran | Lumasiran | Day 1 | 9180 | Geometric Coefficient of Variation 31.7 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Infinity (AUC0-infinity) of Lumasiran | Lumasiran | Month 6 | 8840 | Geometric Coefficient of Variation 40.9 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Infinity (AUC0-infinity) of Lumasiran | Lumasiran | Month 12 | 11900 | Geometric Coefficient of Variation 29.2 | h*ng/mL |
| Area Under the Concentration-time Curve From 0 to Infinity (AUC0-infinity) of Lumasiran | Lumasiran | Month 18 | 11600 | Geometric Coefficient of Variation 48.6 | h*ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03905694/results?page=2